Treatment of chronic pain in the joints and back combined preparationsof chondroitin sulfate and glucosamine hydrochloride

Cover Page

Cite item

Full Text

Abstract

Treating osteoarthritis (OA) and pain in the lower back (LBP) directed primarily to the symptoms of the disease, i.e. to reduce pain and improve functional condition of the joints and spine, which achieved a combination of non-pharmacological and pharmacological methods. appointed by nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, muscle relaxants and other drugs, which do not completely eliminate the symptoms to reduce pain in patients with OA and LBP. However, in patients receiving NSAIDs significantly increased risk of adverse reactions from the gastrointestinal tract, cardiovascular system, kidneys and other organs - this is especially important when comorbid conditions in older patients - that may limit the appointment of a number of drugs. Appointment of a combination of glucosamine and chondroitin sulfate, which has anti-inflammatory and analgesic activity may be useful in the treatment of OA and LBP with regard to the role of inflammation in the pathogenesis of LBP, and structurally modifying properties can be realized with the defeat of the facet joints, has a definite place in the structure of the BNS. However, opinions about the use of these drugs, particularly chondroitin sulfate and glucosamine, is ambiguous. In Russia it was held open multicentre observational prospective study of the effectiveness of this combination in the treatment of knee OA and non-specific LBP in outpatient practice.Analysis of the results of these studies showed a significant decrease in pain, stiffness, improved functional index at Oswestry LBP and WOMAC - in OA, as well as reducing the daily requirement of NSAIDs. There were also marked by good tolerability and high security products.

About the authors

L. I Alekseeva

V.A.Nasonova Research Institute of Rheumatology

Email: alekseeva@irramn.ru
д-р мед. наук, рук. отд. метаболических заболеваний костей и суставов с центром профилактики остеопороза ФГБНУ НИИ ревматологии им. В.А.Насоновой 115522, Russian Federation, Moscow, Kashirskoe sh., d. 34A

E. P Sharapova

V.A.Nasonova Research Institute of Rheumatology

канд. мед. наук, науч. сотр. отд. метаболических заболеваний костей и суставов с центром профилактики остеопороза ФГБНУ НИИ ревматологии им. В.А.Насоновой 115522, Russian Federation, Moscow, Kashirskoe sh., d. 34A

References

  1. Насонов Е.Л. Болевой синдром при патологии опорно - двигательного аппарата. Врач. 2002; 4: 15-9.
  2. Эрдес Ш.Ф., Фоломеева О.М. Ревматические заболевания и инвалидность взрослого населения Российской Федерации. Научно - практическая ревматология. 2007; 4: 4-10.
  3. Галушко Е.А. Медико - социальная значимость ревматических заболеваний. Автореф. дис. … д - ра мед. наук. М., 2011.
  4. Chou R et al. Low Back Pain Guidelines Panel. Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from the American College of Physicians and the American Pain Society.Ann Intern Med 2007; 147: 478-91.
  5. Mc Alindon T.E, Bannuru R.R, Sullivan M.C et al. OARSI guidelines for thenon - surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22 (3): 363-88.
  6. Roelofs P, Deyo R, Koes B et al. Non - steroidal anti - inflammatory drugs for low back pain. Cochrane Database Syst Rev 2008; 23 (1): CD000396.
  7. Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas 2014; 78: 184-7.
  8. Fransen M, Agaliotis M, Nair L et al. Glucosamine and chondroitin for knee osteoarthritis: a double - blind randomised placebo - controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis 2014; 74 (5): 1-8. doi: 10.1136/annrheumdis-2013-203954
  9. Clegg D.O et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354: 795-808.
  10. Jomphe C, Gabriac M, Hale T.M et al. Chondroitin Sulfate Inhibits the Nuclear Translocation of Nuclear Factor - κB in Interleukin-1β-Stimulated Chondrocytes. Basic Clin Pharmacol Toxicol 2007; 102: 59-65.
  11. Martel-Pelletier J et al. First - line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis 2013-203906, doi: 10.1136/annrheumdis-2013-203906 (2013).
  12. Hochbergy M.C et al. The Multicentric Osteoarthritis intervention Study with Sysadoa (MOVES). MOVES Steering Committee. Osteoarthritis Cartilage 2014; 22: S7-S56.
  13. Алексеева Л.И., Чичасова Н.В., Мендель О.И. Рациональный выбор базисной терапии при остеоартрозе. Результаты открытого рандомизированного многоцентрового исследования препарата АРТРА® в России. РМЖ. 2005; 13 (24): 1637-40.
  14. Kocsis J.J, Harkaway S, Snyder R. Biological effects of the metabolites of dimethyl sulfoxide. Ann N Y Acad Sci 1975; 243: 104-9.
  15. Murav'ev Iu.V, Venikova M.S, Pleskovskaia G.N et al. Effect of dimethyl sulfoxide and dimethyl sulfone on a destructive process in the joints of mice with spontaneous arthritis. Patol Fiziol Eksp Ter 1991; 2: 37-9.
  16. Engelke U.F, Tangerman A, Willemsen M.A et al. Dimethyl sulfone in human cerebrospinal fluid and blood plasma confirmed by onedimensional (1)H and two - dimensional (1)H-(13)C NMR. NMR Biomed 2005; 18: 331-6.
  17. Ebisuzaki K. Aspirin and methylsulfonylmethane (MSM): a search for common mechanisms, with implications for cancer prevention. Anticancer Res 2003; 23: 453-8.
  18. Alam S.S, Layman D.L. Dimethyl sulfoxide inhibition of prostacyclin production in cultured aortic endothelial cells. Ann N Y Acad Sci 1983; 411: 318-20.
  19. Beilke M.A, Collins-Lech C, Sohnle P.G. Effects of dimethyl sulfoxide on the oxidative function of human neutrophils. J Lab Clin Med 1987; 110: 91-6.
  20. Usha P, Naidu M. Randomised, double - blind, parallel, placebo - controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Invest 2004; 24: 353-63.
  21. Kim L.S, Axelrod L.J, Howard P et al. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis Cartilage 2006; 14: 286-94.
  22. Pagonis T.A, Givissis P.K, Kritis A.C, Christodoulou A.C. The Effect of Methylsulfonylmethane on Osteoarthritic Large Joints and Mobility. Int J of Orthopaedics 2014; 1 (1): 19-24.
  23. Vidyasagar S, Mukhyaprana P, Shashikiran U et al. Efficacy and Tolerability of Glucosamine Chondroitin Sulphate - Methyl Sulfonyl Methane (MSM) in Osteoarthritis of Knee in Indian Patients. IJPT 2004; 3: 61-5.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).